D. Boral Capital Reiterates Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

Checkpoint Therapeutics (NASDAQ:CKPT)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $4.80 price objective on the stock. D. Boral Capital’s price target suggests a potential upside of 94.33% from the company’s current price.

CKPT has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Lake Street Capital upped their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 16th.

Checkpoint Therapeutics Stock Performance

Shares of CKPT opened at $2.47 on Monday. Checkpoint Therapeutics has a 52 week low of $1.38 and a 52 week high of $4.50. The company has a market capitalization of $120.62 million, a PE ratio of -1.34 and a beta of 1.41. The company’s 50 day moving average price is $3.10 and its 200 day moving average price is $3.08.

Insiders Place Their Bets

In related news, CFO William Garrett Gray sold 74,110 shares of the firm’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total value of $271,983.70. Following the transaction, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at approximately $5,353,223.48. This trade represents a 4.84 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO James F. Oliviero III sold 10,331 shares of Checkpoint Therapeutics stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total transaction of $32,542.65. Following the completion of the transaction, the chief executive officer now directly owns 3,775,019 shares in the company, valued at approximately $11,891,309.85. This represents a 0.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 582,336 shares of company stock valued at $2,156,801 over the last ninety days. Corporate insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Checkpoint Therapeutics

A number of hedge funds have recently bought and sold shares of CKPT. Ameriflex Group Inc. acquired a new stake in shares of Checkpoint Therapeutics in the fourth quarter valued at about $32,000. PUREfi Wealth LLC bought a new stake in Checkpoint Therapeutics during the 4th quarter valued at approximately $32,000. SBI Securities Co. Ltd. acquired a new stake in Checkpoint Therapeutics in the 4th quarter valued at approximately $32,000. Stifel Financial Corp acquired a new stake in Checkpoint Therapeutics in the 4th quarter valued at approximately $32,000. Finally, Tower Research Capital LLC TRC increased its position in Checkpoint Therapeutics by 157.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,616 shares of the company’s stock worth $34,000 after buying an additional 6,486 shares during the period. 22.00% of the stock is currently owned by institutional investors.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.